{"entity":{"id":"nct06391944","kind":"trial","name":"JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations","aka":[],"tldr":"A phase 2 trial of Osimertinib in non-small-cell lung cancer, run by Shanghai JMT-Bio Inc., active and no longer recruiting.","summary":"JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations is a phase 2 interventional study registered as NCT06391944 by Shanghai JMT-Bio Inc., with 161 participants enrolled, started 2021-11-21 and due to reach its primary completion in 2023-05-17. Interventions recorded: JMT101 Injection and Osimertinib tablet.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06391944","url":"https://clinicaltrials.gov/study/NCT06391944"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["osimertinib"],"companies":["cspc"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06391944","phase":"2","setting":"A Phase 2, Open Label, Multi-center Study to Assess the Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-Small Cell Lung Cancer With EGFR Common Mutations","sponsor":"Shanghai JMT-Bio Inc.","enrolled":161,"outcomes":[]},"route":"/trials/nct06391944/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/"}],"company":[{"id":"cspc","kind":"company","name":"CSPC Pharmaceutical Group","route":"/companies/cspc/"}]}}